Innovative Diagnostic Products Arbor Vita Corporation specializes in developing early and accurate diagnostic tools for diseases such as HPV-induced cancers and infectious diseases, including COVID-19, presenting opportunities to partner with healthcare providers and laboratories seeking advanced testing solutions.
Recent COVID-19 Expansion The launch of the CoVisa IgG ELISA test for coronavirus antibodies positions the company to capitalize on ongoing demand for COVID-19 testing, especially among institutions looking for reliable serological assays.
Growing Market Presence With an estimated revenue of up to 50 million dollars and a focus on global health challenges, Arbor Vita holds potential for growth through collaboration with larger biotech and diagnostic companies seeking innovative testing platforms.
Technology Stack Leverage Utilizing advanced web and development technologies like jQuery, PHP, and Elementor, the company demonstrates technical agility that can support scalable distribution, customer engagement, and integration of digital health solutions.
Funding and Revenue Opportunity Given its substantial revenue range and recent product launches, there are opportunities to attract strategic investments or partnerships from larger biotech firms interested in expanding their diagnostic portfolio.